Cinanserin hydrochloride (SQ10643) is a potent, selective, and high-affinity 5-HT2 receptor antagonist (Ki = 41 nM), with significantly greater affinity for 5-HT2 receptors than for 5-HT1 receptors (Ki = 3500 nM). It also acts as an inhibitor of the 3C-like proteinase (3CLpro) of severe acute respiratory syndrome coronavirus (SARS-CoV), effectively reducing viral replication in vitro. Cinanserin and its hydrochloride salt exhibit binding affinity to SARS-CoV 3CLpro and human coronavirus 229E (HCoV-229E) 3CLpro, with KD values of 49.4 μM / 78.0 μM and 18.2 μM / 36.6 μM, respectively. The IC50 values for inhibition of SARS-CoV 3CLpro catalytic activity are 4.92 μM (Cinanserin) and 5.05 μM (Cinanserin hydrochloride), while those for HCoV-229E 3CLpro are 4.68 μM and 5.68 μM, respectively. Neither compound shows inhibitory activity against HRV-14 3Cpro at concentrations up to 200 μM. In vivo, Cinanserin (5 mg/kg, intravenous injection for 2 hours) significantly reduces systemic burn edema and leukocyte-endothelial interactions in male Wistar rats subjected to thermal injury.